Maple PT-141, known in the research literature as bremelanotide, is a synthetic cyclic heptapeptide derived from melanotan II (MT-II), itself an analog of the endogenous melanocortin hormone alpha-melanocyte-stimulating hormone (alpha-MSH). PT-141 peptide research has attracted significant interest due to its unique mechanism of action through central nervous system melanocortin receptors, distinguishing it from peripherally acting compounds studied in similar research contexts. For Canadian researchers sourcing PT-141 for laboratory investigation, understanding its receptor pharmacology and the preclinical evidence base is essential for rigorous experimental design.
Chemical Structure and Molecular Profile of PT-141
Bremelanotide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) is a cyclic heptapeptide with a molecular weight of approximately 1025.2 Da. Its molecular formula is C50H68N14O10. The compound is a deaminated metabolite of melanotan II, retaining the core cyclic lactam ring structure responsible for melanocortin receptor binding while lacking the linear C-terminal extension. This structural modification is significant because it shifts the compound’s receptor selectivity profile compared to its parent molecule, with enhanced activity at the melanocortin-4 receptor (MC4R) relative to melanocortin-1 receptor (MC1R).
Research-grade PT-141 is typically supplied as a lyophilized powder with purity verified by HPLC analysis. At Maple Research Labs, every batch undergoes independent third-party COA verification through Janoshik Analytical to confirm identity and purity, ensuring researchers receive material suitable for reproducible experimental work.
Melanocortin Receptor Pharmacology: MC3R and MC4R Binding
The melanocortin receptor system comprises five G-protein coupled receptor subtypes (MC1R through MC5R), each with distinct tissue distribution and physiological roles. PT-141 demonstrates binding affinity across MC1R, MC3R, and MC4R, but its research significance centers on its agonist activity at MC3R and MC4R, both of which are densely expressed in the hypothalamus and limbic system.
In vitro binding studies using HEK-293 cells expressing recombinant MC4R demonstrated that PT-141 application increases cyclic adenosine monophosphate (cAMP) production in a concentration-dependent manner, confirming agonist activity at this receptor subtype (King et al., Annals of the New York Academy of Sciences, 994:96-102, 2003). The downstream signaling cascade involves activation of protein kinase A (PKA), which promotes neuronal excitability and modulates neurotransmitter release in hypothalamic circuits.
A critical distinction in PT-141 research is its central mechanism of action. Unlike phosphodiesterase-5 (PDE5) inhibitors that act on peripheral vascular smooth muscle, bremelanotide’s pharmacological effects originate in hypothalamic melanocortin pathways. This was established through preclinical studies demonstrating that MC4R knockout animal models show abolished responses to melanocortin agonists, confirming the receptor’s essential role in mediating the compound’s observed effects.
Preclinical Evidence: Hypothalamic Neuron Activation
Foundational preclinical work by King and colleagues (2003) demonstrated that systemic administration of PT-141 to male rats activated hypothalamic neurons, as indicated by increased c-Fos immunoreactivity, a well-established marker of neuronal activation. This neural activation was associated with erectile responses in the animal models, providing early evidence that PT-141 modulates centrally mediated melanocortin pathways rather than peripheral vascular mechanisms.
Further preclinical investigation in both rat and nonhuman primate models confirmed dose-dependent erectogenic responses following PT-141 administration. The specificity of this response was demonstrated through co-administration experiments with melanocortin receptor antagonists, which abolished the observed effects, reinforcing the MC4R-dependent mechanism.
These preclinical findings established a mechanistic framework distinct from existing research compounds in the same therapeutic area. Where PDE5 inhibitors require peripheral nitric oxide signaling, PT-141’s activity originates upstream in central nervous system circuits, suggesting potential research applications in models where peripheral mechanisms are insufficient or compromised.
Novel Research Direction: Melanocortin Receptors and Glioblastoma
A 2024 study published in Anticancer Research (44(9):3875, September 2024) opened an unexpected research avenue for bremelanotide. Researchers found that the melanocortin receptor agonist induced cell death and growth inhibition in glioblastoma cells via suppression of survivin expression. Survivin is a member of the inhibitor of apoptosis (IAP) protein family that is overexpressed in most cancers but largely absent in normal adult tissues.
Key findings from this study included: bremelanotide reduced survivin expression and induced cell death in glioblastoma cells at concentrations that were not cytotoxic to normal human cells. Both effects were reversed in the presence of MC3R/MC4R antagonists, confirming receptor-mediated activity. Additionally, forced overexpression of survivin in glioblastoma cells prevented bremelanotide-induced cell death, establishing a direct mechanistic link between MC3R/MC4R activation, survivin suppression, and apoptosis induction.
The study also demonstrated that bremelanotide promoted cell death induced by established chemotherapeutic agents including temozolomide and osimertinib, suggesting potential combination research applications. This represents a significant expansion of melanocortin receptor research beyond traditional neuroendocrine investigations.
Key Research Findings Summary
- PT-141 is a cyclic heptapeptide (MW ~1025.2 Da, C50H68N14O10) derived from melanotan II with preferential MC4R agonist activity
- In vitro studies in HEK-293 cells confirmed concentration-dependent cAMP production upon MC4R activation (King et al., 2003)
- Preclinical rat studies showed increased c-Fos immunoreactivity in hypothalamic neurons following systemic PT-141 administration, confirming central mechanism of action
- MC4R knockout models demonstrate abolished responses to melanocortin agonists, establishing receptor necessity
- 2024 research in Anticancer Research demonstrated bremelanotide-induced glioblastoma cell death via survivin suppression at concentrations non-toxic to normal cells
- Bremelanotide enhanced temozolomide and osimertinib cytotoxicity in glioblastoma models, suggesting combination research potential
- The RECONNECT Phase 3 program enrolled 1,247 subjects across two 24-week randomized, double-blind, placebo-controlled trials, both meeting co-primary endpoints
Analytical Considerations for PT-141 Research
Researchers working with PT-141 should verify compound identity and purity through reversed-phase HPLC, with research-grade material typically demonstrating purity of 98% or greater. Mass spectrometry (ESI-MS) confirmation of the molecular ion at m/z 1025.2 provides additional identity verification. For detailed guidance on interpreting these analytical results, see our comprehensive COA interpretation guide.
Storage recommendations for lyophilized PT-141 include maintenance at -20 degrees Celsius in a desiccated environment, protected from light. Reconstituted solutions should be used promptly or aliquoted and stored at -20 degrees Celsius to minimize degradation. The cyclic lactam structure provides moderate stability compared to linear peptides, but oxidation of the tryptophan residue remains a primary degradation pathway that researchers should monitor.
PT-141 in the Context of Canadian Peptide Research
The unique central mechanism of PT-141 makes it a valuable research tool for investigating melanocortin receptor signaling in hypothalamic circuits. Canadian researchers can source research-grade peptides from domestic suppliers with same-day shipping, avoiding the delays and customs complications associated with cross-border procurement. This is particularly relevant given the recent closure of major US peptide suppliers, which has accelerated the shift toward Canadian-sourced research materials.
Maple Research Labs provides PT-141 with independent third-party COA verification through Janoshik Analytical, ensuring batch-specific purity documentation that supports reproducible research. For researchers establishing new protocols involving melanocortin receptor agonists, verified compound purity is essential for generating reliable, publishable data.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.